Invokana is the Top Drug Advertising in Medical Journals Through November 2013

by Client Services

Invokana, which launched earlier this year and treats type 2 Diabetes, is the top drug product advertised in medical journals by both pages and dollars through November 2013. Xarelto, which was the top drug advertising in 2012, currently ranks second. In 2011, the product ranked 25 at this point in the year. Many of the products in the top ten launched in this year, including Namenda and Xeljanz.

Top 5 Print Ad Drugs (Dollars): Jan. – November 2013

#1 Invokana – $14 MM (N/A)

#2 Xarelto Tablets - $13 MM (+25%)

#3 Linzess Capsules – $6 MM (N/A)

#4 Tudorza Pressair Inhalation Powder– $6 MM (N/A)

#5 Brilinta Ticagrelor Tablets – $5 MM (+64%)

The percentage changes compare January – November 2013 to that same time period in 2012. For more information on these ad insights or other data, let one of us know.

Kantar Media sets the standard for accurate, comprehensive competitive advertising intelligence in the professional healthcare arena. Check back next month for updated data on the top products, classes, companies and category movers year-to-date.